ArticleStem cell research & therapy2026
Construction of pre-vascularized bone-like tissue by incorporation of mesodermal progenitor cells through simulating endochondral ossification.
Article in Stem cell research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPre-vascularized cartilage enhances bone regeneration (intrachondral osteogenesis) and accelerates bone defect healing. While current strategies focus on co-culturing chondrocytes with endothelial cells, mature endothelial cells inhibit the necessary osteogenic transformation. To overcome this, we implemented a co-differentiation strategy using human induced pluripotent stem cells (hiPSCs)-derived mesodermal progenitor cells (iMPCs) instead. We generated pre-vascularized cartilage aggregates by 3D co-culture of these iMPCs with hiPSC-derived chondrocytes (Chos) and evaluated their osteogenic potential. This approach offers new insights and potential strategies for repairing bone defects.
methodsHiPSCs were differentiated into iMPCs (characterized by FLK1(VEGF-R) expression, CD31/vWF immunofluorescence, tube formation, flow cytometry) and Chos (confirmed by SOX9/COL2/ACAN qRT-PCR, Alcian blue staining, VEGF165 ELISA). Pre-vascularized aggregates were generated by 3D co-culture of iMPCs and Chos in ultra-low attachment plates (monocultures as controls). After 14 days, aggregates were assessed in vitro for vascularization (CD31 immunofluorescence), gene/protein expression (qRT-PCR/immunofluorescence for IHH, ALP, COL1A1), and mineralization (Alizarin Red). In vivo osteogenesis was evaluated by implanting aggregates into rat calvarial defects, analyzing healing at 4/8 weeks via Micro-CT, histology (H&E, Masson's trichrome), and neovascularization (CD31 immunohistochemistry).
resultsIMPCs exhibited high endothelial potential, with a 52.84% induction rate and the ability to form tube-like structures. Co-culture aggregates developed extensive CD31⁺ vascular networks in vitro. Pre-vascularization significantly promoted chondrocyte hypertrophy (increased IHH expression), early osteogenesis (elevated ALP activity and COL1A1 expression), and enhanced in vitro mineralization compared to controls (*p < 0.05). In vivo, the pre-vascularized group demonstrated improved bone defect repair, as shown by increased bone volume in micro-CT analysis, histological evaluation (H&E and Masson's trichrome), enhanced host-derived vascular integration (CD31⁺ staining), and advanced bone maturation relative to control groups (*p < 0.05).
conclusionOur findings indicate that this vascularization approach utilizing mesodermal cells successfully achieves pre-vascularization of cartilage aggregates in vitro, while also facilitating cartilage hypertrophy and early osteogenic transformation. In vivo study revealed that pre-vascularized cartilage aggregates exhibited more nascent vasculature and enhanced bone formation compared to cartilage aggregates alone.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.